EP1677806A4 - Methods for treating acute and overuse sprain and strain using hyaluronic acid - Google Patents

Methods for treating acute and overuse sprain and strain using hyaluronic acid

Info

Publication number
EP1677806A4
EP1677806A4 EP04761743A EP04761743A EP1677806A4 EP 1677806 A4 EP1677806 A4 EP 1677806A4 EP 04761743 A EP04761743 A EP 04761743A EP 04761743 A EP04761743 A EP 04761743A EP 1677806 A4 EP1677806 A4 EP 1677806A4
Authority
EP
European Patent Office
Prior art keywords
sprain
strain
overuse
methods
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04761743A
Other languages
German (de)
French (fr)
Other versions
EP1677806A1 (en
EP1677806B1 (en
Inventor
Robert John Petrella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to SI200431038T priority Critical patent/SI1677806T1/en
Priority to PL04761743T priority patent/PL1677806T3/en
Publication of EP1677806A1 publication Critical patent/EP1677806A1/en
Publication of EP1677806A4 publication Critical patent/EP1677806A4/en
Application granted granted Critical
Publication of EP1677806B1 publication Critical patent/EP1677806B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method for treating acutely or chronically injured soft tissue in an animal or human, the method comprising administering a therapeutically effective amount of HA around the injured soft tissue. The method is useful for the treatment of sprain, strain and shin splints in an animal or human by periarticular administration of a composition comprising HA and a pharmaceutically acceptable carrier. The present invention can be used to potentiate the concomitant treatment of sprain or strain with other therapies.
EP04761743A 2003-10-09 2004-08-27 Methods for treating acute and overuse sprain and strain using hyaluronic acid Active EP1677806B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI200431038T SI1677806T1 (en) 2003-10-09 2004-08-27 Methods for treating acute and overuse sprain and strain using hyaluronic acid
PL04761743T PL1677806T3 (en) 2003-10-09 2004-08-27 Methods for treating acute and overuse sprain and strain using hyaluronic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51068403P 2003-10-09 2003-10-09
PCT/CA2004/001579 WO2005032562A1 (en) 2003-10-09 2004-08-27 Methods for treating acute and overuse sprain and strain using hyaluronic acid

Publications (3)

Publication Number Publication Date
EP1677806A1 EP1677806A1 (en) 2006-07-12
EP1677806A4 true EP1677806A4 (en) 2007-04-04
EP1677806B1 EP1677806B1 (en) 2008-11-19

Family

ID=34421822

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04761743A Active EP1677806B1 (en) 2003-10-09 2004-08-27 Methods for treating acute and overuse sprain and strain using hyaluronic acid

Country Status (14)

Country Link
US (1) US20050080037A1 (en)
EP (1) EP1677806B1 (en)
JP (4) JP2007507431A (en)
CN (1) CN1859918B (en)
AT (1) ATE414522T1 (en)
AU (1) AU2004277290B2 (en)
CA (1) CA2541813C (en)
DE (1) DE602004017888D1 (en)
DK (1) DK1677806T3 (en)
ES (1) ES2317018T3 (en)
PL (1) PL1677806T3 (en)
PT (1) PT1677806E (en)
SI (1) SI1677806T1 (en)
WO (2) WO2005032562A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025255T2 (en) * 2004-12-30 2016-03-29 Genzyme Corp Regimens for intra-articular viscosupplementation
WO2007070617A1 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects
EP1968614A2 (en) * 2005-12-14 2008-09-17 Anika Therapeutics Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
EA014469B1 (en) * 2006-05-11 2010-12-30 Сандра Гоббо Hyaluronic acid binary mixtures and therapeutic use thereof
CA2749034C (en) * 2009-01-07 2019-01-15 Robert John Petrella Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
IT1394570B1 (en) * 2009-07-02 2012-07-05 Fidia Farmaceutici BIOLOGICAL MATERIAL SUITABLE FOR THE OSTEOARTROSIS THERAPY OF TAPER DAMAGE AND FOR THE TREATMENT OF JOINT-PATHOLOGIES.
TWI516269B (en) 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
TWI383796B (en) 2009-08-14 2013-02-01 Holy Stone Healthcare Co Ltd Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
US8575130B2 (en) * 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US20110166099A1 (en) * 2010-01-04 2011-07-07 Wu Tsung-Chung Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US20110166098A1 (en) * 2010-01-04 2011-07-07 Wu Tsung-Chung Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
EP2545925B1 (en) 2011-07-12 2018-02-14 Holy Stone Healthcare Co.,Ltd. Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases
BR112015017040B1 (en) 2013-01-17 2020-11-03 Jeffrey Hagel use of hyaluronic acid to increase muscle muscle volume and alter muscle contour in a human
CN106860706A (en) * 2015-12-10 2017-06-20 仲伟波 Biliquid deletes thorn liquid
KR20190009303A (en) 2016-04-27 2019-01-28 아니카 테라퓨틱스, 인코포레이티드 Compositions for use in the treatment of dry-type degeneration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
MXPA01011542A (en) * 2001-11-13 2003-05-22 Alcon Inc Regeneration of articular cartilage damaged by osteoarthritis i and ii, by means of intra-articular application of sodium hyaluronate and chondroitin sulphate in a gel carrier.
ATE525076T1 (en) * 2002-10-16 2011-10-15 Arthrodynamic Technologies Animal Health Division Inc TREATMENT OF TRAUMATIC SYNOVITIS AND DAMAGED ARTicular cartilage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 1992 (1992-06-01), RAPP H J ET AL: "[Diagnosis and therapy of tendinitis exemplified by the athletic horse]", XP002420134, Database accession no. NLM1641754 *
NIXON A J: "USE OF HYALURONIC ACID FOR TENDON AND TENDON SHEATH DISORDERS IN THE HORSE", JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, vol. 194, no. 12, 1989, & 126TH ANNUAL AMERICAN VETERINARY MEDICAL ASSOCIATION MEETING, ORLANDO, FLORIDA, USA, JULY 15-19, 198, pages 1779, XP009078917, ISSN: 0003-1488 *
SPORTVERLETZUNG SPORTSCHADEN : ORGAN DER GESELLSCHAFT FÜR ORTHOPÄDISCH-TRAUMATOLOGISCHE SPORTMEDIZIN JUN 1992, vol. 6, no. 2, June 1992 (1992-06-01), pages 77 - 88, ISSN: 0932-0555 *

Also Published As

Publication number Publication date
EP1677806A1 (en) 2006-07-12
SI1677806T1 (en) 2009-06-30
AU2004277290A1 (en) 2005-04-14
JP2014205721A (en) 2014-10-30
CN1859918B (en) 2010-07-07
EP1677806B1 (en) 2008-11-19
CN1859918A (en) 2006-11-08
DK1677806T3 (en) 2009-02-23
ES2317018T3 (en) 2009-04-16
PL1677806T3 (en) 2009-05-29
PT1677806E (en) 2009-01-29
CA2541813A1 (en) 2005-04-14
ATE414522T1 (en) 2008-12-15
AU2004277290B2 (en) 2010-05-13
DE602004017888D1 (en) 2009-01-02
CA2541813C (en) 2011-12-06
WO2005032562A1 (en) 2005-04-14
JP2007507431A (en) 2007-03-29
US20050080037A1 (en) 2005-04-14
JP2012236855A (en) 2012-12-06
WO2005034965A1 (en) 2005-04-21
JP2016185989A (en) 2016-10-27

Similar Documents

Publication Publication Date Title
PL1677806T3 (en) Methods for treating acute and overuse sprain and strain using hyaluronic acid
NO20060498L (en) Method of promoting bone growth
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
BR0010669A (en) Method for treating fibrosis using an integrin alpha-4 subunit antagonist
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
HRP20080146T3 (en) Preoperative treatment of post operative pain
SE0400184D0 (en) New therapeutic use
BR0008443A (en) Inhibitors of branched-chain amino acid-dependent aminotranspheres and their use in the treatment of diabetic retinopathy
IS2384B (en) Use of docosahexenoic acid as an active agent for the treatment of lipodystrophy
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
PL1732551T3 (en) Perhexilin for treating chronic heart failure
PT1251850E (en) USE OF A PREPARATION OF COMBINATION IN CANCER THERAPY
MXPA02009603A (en) Divided dose therapies with vascular damaging activity.
RU2010144554A (en) MEANS FOR PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
BRPI0503488A (en) treatment agent for irritable bowel syndrome with predominant diarrhea
NO20043774L (en) The use of devazenide as an analgesic agent
TNSN03022A1 (en) Method for treatment of inflammation
JO2586B1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070307

17Q First examination report despatched

Effective date: 20070914

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI & CIE SA

REF Corresponds to:

Ref document number: 602004017888

Country of ref document: DE

Date of ref document: 20090102

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20090116

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090400187

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E002871

Country of ref document: EE

Effective date: 20090217

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2317018

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E005079

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20090820

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20090825

Year of fee payment: 6

Ref country code: DK

Payment date: 20090828

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20090818

Year of fee payment: 6

Ref country code: SE

Payment date: 20090824

Year of fee payment: 6

Ref country code: LU

Payment date: 20090821

Year of fee payment: 6

Ref country code: HU

Payment date: 20090902

Year of fee payment: 6

Ref country code: FI

Payment date: 20090820

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20090824

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20090826

Year of fee payment: 6

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100828

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100827

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100827

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100828

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: 2405871 ONTARIO INC., CA

Free format text: FORMER OWNER: PETRELLA, ROBERT JOHN, CA

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E002871

Country of ref document: EE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 5492

Country of ref document: SK

Owner name: 2405871 ONTARIO INC., LONDON, ONTARIO, CA

Free format text: FORMER OWNER: PETRELLA ROBERT JOHN, LONDON, ONTARIO, CA

Effective date: 20170926

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20170907 AND 20170913

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: 2405871 ONTARIO INC.; CA

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: ROBERT JOHN PETRELLA

Effective date: 20170726

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: 2405871 ONTARIO INC.

Effective date: 20171025

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004017888

Country of ref document: DE

Representative=s name: MEISSNER BOLTE PATENTANWAELTE RECHTSANWAELTE P, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004017888

Country of ref document: DE

Owner name: 2405871 ONTARIO INC., LONDON, CA

Free format text: FORMER OWNER: PETRELLA, ROBERT, LONDON, ONTARIO, CA

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: 2405871 ONTARIO INC., CA

Effective date: 20171221

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: 2405871 ONTARIO INC.; CA

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AFFECTATION / CESSION; FORMER OWNER NAME: PETRELLA, ROBERT JOHN

Effective date: 20170727

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 414522

Country of ref document: AT

Kind code of ref document: T

Owner name: 2405871 ONTARIO INC., CA

Effective date: 20180110

REG Reference to a national code

Ref country code: ES

Ref legal event code: GD2A

Effective date: 20180219

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: DE

Ref legal event code: R088

Ref document number: 602004017888

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230826

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230822

Year of fee payment: 20

Ref country code: ES

Payment date: 20230901

Year of fee payment: 20

Ref country code: EE

Payment date: 20230801

Year of fee payment: 20

Ref country code: CZ

Payment date: 20230810

Year of fee payment: 20

Ref country code: CH

Payment date: 20230903

Year of fee payment: 20

Ref country code: AT

Payment date: 20230802

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230801

Year of fee payment: 20

Ref country code: PT

Payment date: 20230807

Year of fee payment: 20

Ref country code: PL

Payment date: 20230807

Year of fee payment: 20

Ref country code: DE

Payment date: 20230829

Year of fee payment: 20

Ref country code: BE

Payment date: 20230828

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240216

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240219

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240220

Year of fee payment: 20

Ref country code: GB

Payment date: 20240215

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240215

Year of fee payment: 20

Ref country code: FR

Payment date: 20240216

Year of fee payment: 20